期刊
EXPERT REVIEW OF NEUROTHERAPEUTICS
卷 10, 期 7, 页码 1201-1208出版社
TAYLOR & FRANCIS LTD
DOI: 10.1586/ERN.10.74
关键词
Alzheimer's disease; antioxidants; oxidative stress; therapeutics
资金
- Anavex
- Canopus BioPharma
- Medivation
- Neurotez
- Neuropharm
- Panacea Pharmaceuticals
- Voyager Pharmaceuticals
Oxidative stress is an important factor, and one that acts in the earliest stages, of Alzheimer's disease (AD) pathogenesis. The reduction of oxidative stress has been tested as a therapy for AD. While the trial of vitamin E supplementation in moderately severe AD is the most promising so far, it also reveals the limitations of general antioxidant therapies that simply lower oxidative stress and, therefore, the complexity of the redox system. The multiple contributing factors that foster the clinical manifestations of AD should be considered when designing antioxidative stress therapy. In this article, we discuss the multiple pathogenic mechanisms of oxidative stress in AD and the potential targeting approaches.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据